The vision of the MPP is a world
in which people in low- and
middle-income countries have rapid
access to affordable and appropriate
HIV, hepatitis C and tuberculosis
In 2016, the MPP moved to expand
existing HIV licensing agreements
and ramp up its work with generic
manufacturing partners to bring
Ten companies are now licensed to
produce daclatasvir, with the MPP
adding three new licensees in 2016,
Beximco, Sandoz and Zydus Cadila, to
manufacture the treatment.
TB Alliance and the MPP signed a
Memorandum of Understanding in
April outlining a collaboration to
encourage the development
of new TB regimens.
With its manufacturing partners, the
MPP continued to intensify its efforts
to expedite the development of
generic versions of hepatitis C and
HIV medicines in 2016.
and Report of the Statutory Auditor.